Spyre Therapeutics Inc. research snapshot
SYRE AI stock analysis as of the August 4, 2026 data cutoff reads Spyre Therapeutics as a clinical-stage biotechnology company with no approved products or revenue, now trading at $94.93 after closing down 3.46% on August 3, 2026. The stock has risen 483.83% over 52 weeks as SPY001 delivered strong SKYLINE Part A induction data on April 13, 2026 and SPY002 met its primary endpoint in the SKYLINE Part A ulcerative colitis trial in June 2026, but the company remains pre-revenue, burned $57.4 million of cash in Q1 2026, and its $8.35 billion market cap is priced entirely on pipeline probability. This page is an information tool, not investment advice.
Current price
$94.93 at the August 3, 2026, 4:00 PM EDT market close, down 3.40 or 3.46% from the $98.33 July 31 close, after opening at $97.15 and trading in a session range of $92.71 to $99.58 on the real-time quote, with an after-hours quote of $96.82, up 1.89 or 1.99%, and the 52-week high of $105.09 set on July 14, 2026 remaining above
Market cap
$8.35 billion reported by StockAnalysis.com at the August 3, 2026 market close, matching the $94.93 price times 87.94 million shares outstanding, with the Q1 2026 Form 10-Q cover listing 86,841,253 shares of common stock outstanding as of April 28, 2026 and shares rising 29.57% year over year
AI score
42 / 100
Rating
Clinical-stage biotech with high uncertainty
Trend status
Strong uptrend over the past 52 weeks up 483.83% from the $14.51 low, trading below the 5-day and 20-day moving averages near $98.52 and $98.46 while holding above the 50-day and 200-day moving averages near $88.12 and $52.75
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Spyre is a pre-revenue biotech with no approved products. Its business quality depends entirely on pipeline execution across SPY001 (a4b7), SPY002 and SPY072 (anti-TL1A), and SPY003 (anti-IL-23). The SKYLINE Part A induction data for SPY001 and SPY002 are encouraging, but commercial viability remains unproven. | Low |
| Moat | Pending any approved products, the moat is minimal and untested. Potential moat drivers are long-acting antibody engineering, co-formulatable fixed-dose combinations, and first-mover data in novel dual-target regimens, but these are not yet validated by approved products or issued commercial-stage patents. | Low |
| Management | Management has credible biotech development experience and a $741.5 million cash position built through disciplined financing, including a $296.4 million October 2025 offering at $18.50 and an ATM program. Insiders own 5.77%, which is a modest but not large alignment signal. The $30.0 million Q1 2026 gain on sale of an in-process R&D asset shows portfolio management activity. Split view. | Medium |
| Financial trend | No revenue. Q1 2026 net loss of $69.0 million and net cash used in operating activities of $57.4 million, with $741.5 million of cash and marketable securities as of March 31, 2026. FY2025 net loss was $155.2 million, FY2024 was $208.0 million, and FY2023 was $338.8 million, so the burn is substantial and rising as trials scale. | High |
| Valuation | At $94.93, market cap of $8.35 billion with no revenue, negative EPS, and negative FCF yield of 2.22%. Price/Book of 15.05x reflects the market pricing in pipeline probability, not current earnings. Enterprise value of $7.61 billion sits modestly below market cap because of the $741.47 million net cash position. | Medium |
| Technical trend | 52-week range $14.51 to $105.09, up 483.83% over the trailing 52 weeks. Closed at $94.93 on August 3, 2026 below the 5-day and 20-day moving averages near $98.52 and $98.46, above the 50-day and 200-day moving averages near $88.12 and $52.75, with RSI near 49.58 and beta of 3.02. | Medium-high |
| Risk level | Very high. Pre-revenue binary biotech risk with clinical failure, competitive, dilution, and financing risks. About 12.51 million shares short, 14.22% of shares outstanding, adds squeeze and unwind dynamics. The stock can gap sharply on trial data, and beta of 3.02 amplifies market moves. | High |
| AI confidence | Descriptive confidence is high for reported financials, market data, and analyst targets. Forward-return confidence is low because the stock is a binary clinical-stage biotech with high dependency on unread Part B, SKYWAY, and registration trial results. | Medium data confidence |
| Investment certainty | Low. The thesis hinges on clinical data readouts and competitive positioning. A margin-of-safety approach would require deep biotech domain knowledge that general AI analysis cannot replace. | Low |
SYRE AI stock forecast
The SYRE AI stock forecast is a scenario range, not a precise prediction. EPS-based three-scenario math is not meaningful because Spyre has negative EPS and no revenue. The more useful framework compares pipeline probability of success, peak sales estimates for IBD and rheumatic therapies, cash runway into 2027 to 2028, and comparable biotech valuations. The 17-analyst consensus is Strong Buy with an average target of $105.79, 11.44% above the August 3, 2026 close.
$140 to $180
More likely if SPY002 and SPY001 deliver strong Part B combination data, SPY072 shows competitive efficacy in the SKYWAY rheumatic basket, SPY003 reaches the clinic with a differentiated profile, or Spyre signs a major partnership or licensing deal. A clear regulatory and commercial path toward the early 2030s launch window would also support upside.
$95 to $120
More likely if data continue to look adequate but not clearly best-in-class versus Roche, Merck, and other IBD competitors, and the market keeps pricing the stock around the consensus target of $105.79 with standard clinical-stage attrition risk. Expect moderate volatility around each data event.
$25 to $55
More likely if SPY002 or SPY001 fail to maintain efficacy through maintenance and registration phases, Part B combinations disappoint on safety or efficacy, SPY072 fails in rheumatic indications, competitors demonstrate superiority, or cash burn forces a dilutive financing before value-creating milestones.
SYRE AI technical analysis
SYRE technical analysis as of the August 4, 2026 data cutoff shows a strong uptrend that has decelerated. The stock closed at $94.93 on August 3, 2026, up 483.83% over 52 weeks from the $14.51 low, but it now sits below its 5-day and 20-day moving averages near $98.52 and $98.46 after the June SPY002 catalyst cooled, while holding above the 50-day and 200-day moving averages near $88.12 and $52.75. RSI near 49.58 is neutral, beta of 3.02 means amplified moves, and the next earnings report is due August 6, 2026, which typically raises volatility.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $94.93 | StockAnalysis.com real-time quote at the August 3, 2026, 4:00 PM EDT market close, down 3.40 or 3.46% from the $98.33 July 31 close after opening at $97.15 and trading in a session range of $92.71 to $99.58, with an after-hours quote of $96.82 up 1.89 or 1.99%. |
| Resistance (52-week high) | $105.09 | 52-week high set on July 14, 2026 and the primary overhead resistance for any renewed breakout attempt. |
| Resistance (moving average cluster) | $98 to $103 | The 5-day moving average near $98.52 and the 20-day moving average near $98.46 computed from the StockAnalysis.com daily price history form an immediate overhead zone, with the July highs near $102 to $103 as secondary resistance. |
| Support (near-term) | $92 to $94 | Recent consolidation zone around the August 3 session low of $92.71 and the $94 close, a first near-term support area. |
| Support (50-day MA) | $88.12 | StockAnalysis.com statistics reported the 50-day moving average near $88.12, a meaningful medium-term support reference on pullbacks. |
| Support (200-day MA) | $52.75 | StockAnalysis.com statistics reported the 200-day moving average near $52.75, the longer-term trend reference that would signal a major breakdown if lost. |
| Momentum | RSI near 49.6 | 14-day RSI near 49.58 on StockAnalysis.com statistics as of August 3, 2026, neutral after the strong June rally and the subsequent cooling. |
| Volume | About 1.09 million average shares | StockAnalysis.com statistics listed 20-day average volume near 1.09 million shares, with volume spikes around data releases and the July 14 52-week high session. |
| Beta | 3.02 | High beta. The stock tends to amplify market moves by roughly 3x, so position sizing must account for larger swings. |
| Invalidation | Close below $88.12 | A decisive close below the 50-day moving average near $88.12 would weaken the medium-term uptrend, and a close below the $80 area would signal a deeper technical breakdown toward the 200-day trend line. |
SYRE AI trading strategy
The SYRE AI trading strategy provides frameworks for monitoring, not personalized advice. Clinical-stage biotech stocks require position sizing that accounts for binary event risk, catalyst calendars, liquidity during data events, and gap-risk management. The next high-impact event is the Q2 2026 earnings report due August 6, 2026.
Build a watchlist of key catalyst dates: Q2 2026 earnings on August 6, 2026, SPY002 and SPY001 SKYLINE Part B data, SPY072 SKYWAY readouts in rheumatic disease, and SPY003 clinical entry. Enter small positions into pre-data weakness with a defined invalidation level below support, and take partial profits into strength after positive results. Be prepared for gaps in either direction on data day.
Position size should not exceed 2 to 5% of a portfolio given binary risk. Use a hard stop below the last major support level or reduce to cash before high-impact data events.
If the stock holds above the 50-day moving average near $88.12 and the 200-day moving average near $52.75, consider buying pullbacks toward the 50-day or defined support zones with a trailing stop below the most recent swing low. A reclaim of the 5-day and 20-day moving average cluster near $98 would signal momentum resuming.
Trend-following in high-beta biotech requires wider stops. Monitor volume: declining volume on up-moves may signal trend exhaustion. Reduce exposure before catalyst events such as the August 6, 2026 earnings report.
Monitor the 12.51 million shares short, 14.22% of shares outstanding, which creates squeeze and unwind risk around positive data. A rally above the 52-week high of $105.09 with strong volume could accelerate if shorts are forced to cover.
Do not build a large short position into binary data events because positive trial results can trigger violent upside squeezes. If watching the short side, use tight invalidation above recent resistance.
Investment research summary
Spyre Therapeutics is developing long-acting antibody therapies and co-formulatable fixed-dose combinations for inflammatory bowel disease (ulcerative colitis and Crohn disease) and rheumatic diseases (rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis). It has no approved products or revenue. Value depends entirely on pipeline success across the a4b7 program (SPY001), anti-TL1A programs (SPY002 and SPY072), and the anti-IL-23 program (SPY003).
No current product moat. Potential future moat drivers include long-acting antibody engineering that enables quarterly to twice-yearly dosing, co-formulatable fixed-dose combinations, and early proof-of-concept data in dual-target IBD regimens. These are unproven. Competitive risk is high: Roche, Merck, and other large pharma are advancing IBD and anti-TL1A programs that can match or exceed Spyre resources.
The most likely failure paths are: (1) SPY001 or SPY002 induction responses do not convert into maintenance or Part B combination efficacy; (2) SPY072 fails in rheumatic indications; (3) safety signals emerge from dual immunosuppression combinations; (4) competitors such as Roche and Merck demonstrate superior or faster profiles; (5) cash burn forces a dilutive offering before value-creating milestones; (6) the company needs further financing to reach the early 2030s commercial launch.
Management has relevant biotech development experience and has raised capital effectively, including a $296.4 million net October 2025 offering at $18.50 per share and a $200 million ATM program with $154.1 million remaining as of March 31, 2026. Insiders own 5.77%, a modest alignment signal. The $30.0 million Q1 2026 gain on sale of an in-process R&D asset shows active portfolio management. Capital allocation will be tested as trials scale and the runway into 2027 to 2028 is managed.
IBD is a large and growing market with significant unmet need, and anti-TL1A has become one of the most closely watched mechanisms in the space, drawing large pharma investment. Spyre competes in a hot area where deep-pocketed players can move quickly. The long-acting dosing and combination strategy is differentiated but unproven. Success depends on converting early induction data into durable efficacy across indications and combinations.
At $8.35 billion market cap with no revenue, Spyre trades at a premium to many pre-commercial biotechs, with a 15.05x price/book and negative FCF yield of 2.22%. The $741.47 million net cash position gives an enterprise value of $7.61 billion. The consensus target of $105.79 is only 11.44% above the August 3, 2026 close, so the upside is modest versus the binary risk. Margin of safety depends on whether pipeline probability justifies the current price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| SYRE price | $94.93 at the August 3, 2026, 4:00 PM EDT market close, down 3.40 or 3.46% from the $98.33 July 31 close, after opening at $97.15 and trading in a session range of $92.71 to $99.58, with an after-hours quote of $96.82 up 1.89 or 1.99% | StockAnalysis.com real-time quote | August 4, 2026 |
| Market capitalization | Near $8.35 billion, reported by StockAnalysis.com at the August 3 market close and matching the $94.93 price times 87.94 million shares outstanding, verified with the financial_rigor market cap check (deviation 0.02%) | StockAnalysis.com quote and statistics, financial_rigor verification | August 4, 2026 |
| Shares outstanding | 87.94 million shares as of August 3, 2026, up 29.57% year over year and 4.61% quarter over quarter, with the Q1 2026 Form 10-Q cover listing 86,841,253 shares of common stock outstanding as of April 28, 2026 | StockAnalysis.com statistics and Q1 2026 Form 10-Q | August 4, 2026 |
| Cash and marketable securities | $741.47 million as of March 31, 2026, with cash and cash equivalents of $97.185 million and marketable securities of $644.282 million, matching the Q1 2026 Form 10-Q | StockAnalysis.com balance sheet and Q1 2026 Form 10-Q | August 4, 2026 |
| Net cash and enterprise value | Net cash of $741.47 million, or about $8.43 per share, with no debt, giving an enterprise value of about $7.61 billion against the $8.35 billion market cap | StockAnalysis.com statistics | August 4, 2026 |
| EPS (TTM) | -$2.17 | StockAnalysis.com statistics | August 4, 2026 |
| Net income (TTM) | -$148.70 million | StockAnalysis.com statistics | August 4, 2026 |
| Operating cash flow and free cash flow (TTM) | Operating cash flow of about -$185.63 million and free cash flow of about -$185.63 million over the trailing twelve months | StockAnalysis.com cash flow data | August 4, 2026 |
| Q1 2026 results | Net loss of $69.0 million in Q1 2026 with research and development expense of $60.4 million and general and administrative expense of $15.2 million, partially offset by a $30.0 million gain on sale of in-process R&D, and net cash used in operating activities of $57.4 million | Q1 2026 Form 10-Q | August 4, 2026 |
| FY2025 to FY2023 net losses | Net loss of $155.2 million in FY2025, $208.0 million in FY2024, and $338.8 million in FY2023, with an accumulated deficit of $1.2 billion as of March 31, 2026 | Q1 2026 Form 10-Q | August 4, 2026 |
| Price/Book and FCF yield | Price/Book of 15.05x and negative free cash flow yield of 2.22%, with return on equity of -31.11% | StockAnalysis.com statistics | August 4, 2026 |
| Beta and 52-week range | Beta of 3.02, 52-week range $14.51 to $105.09, and 52-week price change of +483.83% | StockAnalysis.com quote and statistics | August 4, 2026 |
| Moving averages and RSI | 50-day moving average near $88.12, 200-day moving average near $52.75, 14-day RSI near 49.58, and 20-day average volume near 1.09 million shares | StockAnalysis.com statistics | August 4, 2026 |
| Short interest | About 12.51 million shares short, 14.22% of shares outstanding and 15.24% of float, with 6.57 days to cover, down from 13.64 million the prior month | StockAnalysis.com statistics short selling | August 4, 2026 |
| Analyst consensus | Strong Buy with an average price target of $105.79 across 17 analysts, low $88, median $105, and high $135, about 11.44% above the August 3, 2026 close | StockAnalysis.com forecast | August 4, 2026 |
| Recent analyst actions | Deutsche Bank raised to $135 on June 23, 2026, Mizuho raised to $120 on July 13, 2026, Guggenheim reiterated $115 on July 25, 2026, LifeSci reiterated $119, BTIG maintained $112, and Wolfe Research downgraded to Peer Perform without a price target on July 28, 2026 | StockAnalysis.com ratings | August 4, 2026 |
| Ownership | Institutional ownership of 91.28% and insider ownership of 5.77%, with a float of 82.07 million shares | StockAnalysis.com statistics | August 4, 2026 |
| Employees and listing | 112 employees, listed on NASDAQ under SYRE, industry biotechnology, sector healthcare | StockAnalysis.com quote and profile | August 4, 2026 |
This SYRE AI stock analysis page is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, and third-party data as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, clinical trial results, financing events, competitive developments, or market moves. Spyre Therapeutics is a clinical-stage biotechnology company with no approved products or revenue, making it a high-risk investment. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
